Variations in second-shell (orange) and third-shell (green) residues are identified outside the conserved binding pocket (first-shell, yellow) 
(pink) to human iNOSox is very similar to that of compound 3 in murine iNOSox (a).
Inhibitor 9 binding further induces conformational changes in second-shell Asn, which fits in a hydrophobic pocket created by third-shell Val305 and Phe286 (green). 
Quinazolines and aminopyridine binding to iNOSox
Quinazoline inhibitors share a common (di)-fluoro-quinazoline amine core (black in Fig. 1 ), but have different tails (magenta in Fig. 1 ), corresponding to thienyl (1), furanamido-ethyl (2), cyano-pyridylcarbonyl spiro-piperidinyl (3), aminomethylbenzoyl spiro-piperidinyl (4), and cyano-benzoyl spiro-piperidinyl (5) moieties.
Aminopyridine inhibitors share a 4-methyl-2-aminopyridine core (compound 6, black in Fig. 1 ) and can either be 6-substituted (7) (8) or N-substituted (9-12). Compounds and pack more parallel to the heme plane than compounds 9-12 (average interplanar angles of 13° and 26°, respectively), thus possibly explaining their improved potency in iNOS (Fig. 1, Supplementary Fig. 2 ).
We explored permissive substitutions of compound 9 (Supplementary Table 1 ).
Changing the 4-methyl group in compound 9 into chlorine (compound 10) slightly decreases the inhibitor potency in all three isozymes. However, substitution with a 4-methoxy group (compound 11) improves potency 3 fold against iNOS without affecting potency in the other isoforms, thus contributing to increased isozyme selectivity (1111 fold against eNOS, 333 fold against nNOS). Further elaboration of the piperidine acyl group to a substituted benzamide (compound 12) affords excellent selectivity against eNOS (1351 fold) and nNOS (81 fold).
Bulky inhibitors induce conformational changes in iNOSox
We superimposed the x-ray structures of murine iNOS bound to N-hydroxy-Larginine (NOHA, PDB entry 1DWW 1 ), small inhibitor 6 and highly selective 3a ) and aminopyridine ( Supplementary Fig. 3b ) inhibitors bind like the NOHA (Supplementary Fig. 3c ) and L-Arg guanidinium groups 4 , via heme stacking and anchoring hydrogen bonds to Glu. The NOHA carboxylate group is tethered by hydrogen bonds to Tyr367/373 and Gln in the "carboxylate pocket", which was proposed to exclude inhibitors larger than L-Arg or not based on amino acid L-Arg 5 .
In the iNOSox complex with intermediate NOHA or small compound 6 (Fig. 2a) , firstshell Gln hydrogen bonds to Tyr, and Arg hydrogen bonds to Ser256/262 (Supplementary Fig. 3c ). In contrast, we observe that the longer, rigid and bulky tail of compound 3 (and compounds 9 and 12) forms a hydrogen bond from Tyr to the inhibitor carbonyl oxygen atom (Fig. 2b-d, Supplementary Fig. 3 ). In addition, the side chains of invariant first-shell residues Gln (r.m.s.d. value of 3.3 Å), Arg (0.6 Å) and Arg382/388 (0.7 Å) show significant changes that lead to the opening of the new Gln specificity pocket in these complexes. In murine iNOS, the Arg side-chain rotation is accommodated by the small size of Thr277 and no further compensatory propagation of side-chain movements, like the ones observed in human iNOS, occurs ( Fig. 2, Supplementary Fig. 4 ). Binding of compound 1, with its smaller tail, induces smaller rotations of Gln and Arg and no rotation of Arg382/388, leading to partial opening of the Gln specificity pocket (Supplementary Fig. 2a) . Importantly, all
iNOSox structures in complex with bulky inhibitors bearing rigid extended tails present the Gln-open conformation and corresponding side-chain conformations for
Arg and Arg382/388 (Supplementary Fig. 2 ). Thus, we predict that these inhibitors will all induce the same cascade of side-chain rotations observed in human iNOSox upon compound 9 binding.
Compound 9 binding to eNOSox and iNOSox
The eNOSox protein overall structure and active site closely resemble those of iNOSox. The structures of eNOSox and iNOSox with compound 9 superimpose with an overall r.m.s. deviation of 0.8 Å (same for both human and murine iNOSox). In eNOS, the anchoring hydrogen bonds to active site Glu place the aminopyridine core almost parallel to the heme plane (interplanar angle is ~20° in eNOS vs. 30° in iNOS), and the bulky tail packs between the heme propionates and with conserved residue Val337/346/352 (Supplementary Fig. 6 ). This position of the rigid inhibitor tail induces slight side-chain rotations of Trp448/457/463 on the propionate A side, and of Tyr476/485/491 on the propionate B side. Thus, both the core and the extended tail of aminopyridine compound 9 interact more closely with the eNOS heme than with the iNOS heme.
Interestingly, in the eNOS:compound 9 complex, the heme is more planar than in iNOS (see below) and a second inhibitor molecule now occupies the pterin site ( Supplementary Fig. 6a ). The aminopyridine core of this second inhibitor molecule lies almost perpendicular to the heme plane, and stacks with pterin-site residue 
Differences in pterin occupancy between eNOS and iNOS
The second inhibitor molecule in eNOSox mimics H4B binding but cannot substitute for its essential structural, allosteric, and electronic roles 6 in NOS catalysis. The nearly identical pterin-binding sites of the three NOS isozymes exhibit comparable H4B affinities 7 , but differing crystallographic occupancies. In eNOS crystal structures, pterin replacement by inhibitor, solvent, cryoprotectant, and substrate is common [8] [9] [10] , whereas the H4B sites in iNOS and nNOS x-ray structures are always occupied by pterin 1, 11, 12 (Supplementary Tables 3-5) .
Structural comparisons of the NOS isozymes provide insights into the origin of this eNOS peculiarity. In the H4B sites, the π-stacking residues (Trp448/457/463 and Phe461/470/476) and Arg366/375/381 are conserved among isozymes, and most hydrogen bonds are made with main-chain carbonyl oxygen atoms 4 . The only side chains that differ between the eNOS and iNOS H4B sites are Ala447/Ile456/Ile462
(bovine eNOS/murine iNOS/human iNOS numbering) and Val105/Met114/Met120
(corresponding to human nNOS Val682 and Met340, respectively). In iNOS (and nNOS), the bulky Met114 side chain more effectively sequesters pterin from solvent and makes tighter hydrophobic contacts with H4B C4 and N5 atoms than does the smaller Val side-chain in eNOS 13 . Accordingly, the eNOS pterin site can accommodate solvent molecules next to H4B to fill the void left by the smaller Val side chain 14 .
The H4B environment in NOS influences the formation and stability of the transient cationic H4B radical, which forms during NO synthesis and is localized predominantly at the N5 position 15, 16 . The N5-methyl H4B analog (5Me-H4B), which also supports NO synthesis 17 , significantly accelerates radical formation and greatly enhances radical stability in all three isozymes 18 . Comparison of the murine iNOS xray structures bound to 5Me-H4B vs. H4B shows no major structural differences 19 , but reveals that the bulky Met114 thiomethyl group packs closer to 5Me-H4B. Among the three NOS isozymes, eNOS, which lacks this thiomethyl, presents the slowest formation and the fastest decay rates for the H4B radical 18 . Isozyme-specific differences in the pterin-binding site of NOS may also facilitate H4B exchange in eNOS. Comparisons of the iNOS and eNOS complexes with aminopyridine compound 9 (Supplementary Fig. 6 ) suggest isozyme-specific differences in both the H4B and L-Arg binding sites that could impact H4B replacement. In the H4B site, the bulky Met side-chain in iNOS (and nNOS) may preclude eNOS-like inhibitor binding. In the L-Arg site, the packing of the rigid and bulky compound 9 tail between the heme propionates in eNOS is associated with shifts in conserved Trp448/457/463, which is important for stabilizing H4B binding 11 . Thus, our studies prompt the hypotheses that (i) the increased openness and solvent accessibility of the eNOS pterin site and/or (ii) aminopyridine binding in the eNOS active site facilitates inhibitor replacement of H4B. Regardless of the mechanism, aminopyridine binding to eNOS likely inhibits NO synthesis by disrupting H4B binding.
Differences in heme planarity between eNOS and iNOS
From structural comparisons of iNOS and eNOS bound to aminopyridine compound 9 ( Supplementary Fig. 6 ) and other inhibitors, we found the eNOS heme to be more planar and less distorted than its iNOSox counterpart. To quantify the degree of heme distortion in NOSox structures, we applied the normal-coordinate structural decomposition method 20 , which classifies heme distortions into low-energy vibrational modes including ruffling, saddling, doming, waving, and pyrrole propellering deformations. In iNOSox complexes with compounds 1-10, we found that the average heme out-of-plane distortion is 0.8 Å vs. 0.5 Å in 20 eNOSox structures (our unpublished results). In the compound 9 complexes reported here, the average heme out-of-plane distortion is again significantly greater in iNOSox (1.0 Å) than in eNOSox (0.6 Å; Methods). Our results indicate that all NOS isozymes exhibit significantly distorted heme conformations. In other heme-containing proteins, even lesser distortions have been shown to tune optical and redox properties, and thus play significant biological roles 21 . In NOS, distortional differences of the heme among the three isozymes may be linked to different coupling interactions of heme with pterin and different degrees of NOS self-inhibition by the product NO 22, 23 , and thus have important implications for isozyme-specific regulation.
The double human iNOSox mutant mimics eNOSox
To test the role of isozyme-specific third-shell residues, we mutated human iNOSox Phe286 into Ile and Val305 into Leu to mimic human eNOSox. Human iNOSox carrying the double mutation Phe286Ile/Val305Leu exhibited the UV-visible spectral properties of wild-type human iNOSox, indicating that these mutations do not perturb enzyme structure or the heme electronic environment. To confirm this result, we determined the x-ray structure of the human iNOSox double mutant (Methods) cocrystallized with excess compound 9 (55-fold molar excess), and showed that the Gln specificity pocket and inhibitor are not present (Supplementary Fig. 7 ).
Supplementary Methods

Synthesis of Compounds 13-16
Compound 15a: tert-Butyl N-(1-hydroxypentan-2-yl)carbamate (R,S)-2-Aminopentanol (9.25 g, 90 mmol) was dissolved in dry tetrahydrofuran (100 ml) and treated with pyridine (7.9 g, 100 mmol). The solution was cooled in an ice bath and stirred under a nitrogen atmosphere. Di-tert-butyldicarbonate (19.6 g, 90mmol) was added and the mixture was allowed to warm up to ambient temperature over 18hr with stirring. The mixture was poured into aqueous 2 M hydrochloric acid and the product was extracted using ethyl acetate. The ethyl acetate was removed under reduced pressure to give the product 15a as a clear oil (16.7 g ). 
Supplementary Movie 1 Legend
The Quicktime movie illustrates the cascade of conformational changes that occur in human iNOSox upon aminopyridine compound 9 binding (Quicktime, 582 kB).
